Roche Holding AG (RHHBF)
USD 303.32
(0.0%)
USD 303.32
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 15.39 Billion CHF | -11.91% |
| 2022 | 17.47 Billion CHF | -3.74% |
| 2021 | 18.15 Billion CHF | -2.09% |
| 2020 | 18.54 Billion CHF | 5.67% |
| 2019 | 17.54 Billion CHF | 18.82% |
| 2018 | 14.76 Billion CHF | 13.58% |
| 2017 | 13 Billion CHF | -7.58% |
| 2016 | 14.06 Billion CHF | 1.79% |
| 2015 | 13.82 Billion CHF | -1.91% |
| 2014 | 14.09 Billion CHF | -13.96% |
| 2013 | 16.37 Billion CHF | 15.94% |
| 2012 | 14.12 Billion CHF | 4.99% |
| 2011 | 13.45 Billion CHF | -0.24% |
| 2010 | 13.48 Billion CHF | 9.85% |
| 2009 | 12.27 Billion CHF | -11.83% |
| 2008 | 13.92 Billion CHF | -3.76% |
| 2007 | 14.46 Billion CHF | 23.34% |
| 2006 | 11.73 Billion CHF | 35.31% |
| 2005 | 8.66 Billion CHF | -3.45% |
| 2004 | 8.97 Billion CHF | 60.57% |
| 2003 | 5.59 Billion CHF | 318.88% |
| 2002 | 1.33 Billion CHF | -58.89% |
| 2001 | 3.24 Billion CHF | -54.47% |
| 2000 | 7.13 Billion CHF | 11.06% |
| 1999 | 6.42 Billion CHF | 46.9% |
| 1998 | 4.37 Billion CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 4.53 Billion CHF | 0.0% |
| 2024 Q1 | 4.53 Billion CHF | -34.19% |
| 2023 FY | 15.39 Billion CHF | -11.91% |
| 2023 Q3 | 3.56 Billion CHF | -62.32% |
| 2023 Q4 | 6.89 Billion CHF | 93.41% |
| 2023 Q2 | 9.45 Billion CHF | 77.56% |
| 2023 Q1 | 5.32 Billion CHF | -32.62% |
| 2022 FY | 17.47 Billion CHF | -3.74% |
| 2022 Q4 | 7.9 Billion CHF | 89.0% |
| 2022 Q1 | 6.1 Billion CHF | -24.23% |
| 2022 Q2 | 10.27 Billion CHF | 68.31% |
| 2022 Q3 | 4.18 Billion CHF | -59.28% |
| 2021 Q1 | 5.29 Billion CHF | -32.85% |
| 2021 FY | 18.15 Billion CHF | -2.09% |
| 2021 Q3 | 4.83 Billion CHF | -47.62% |
| 2021 Q4 | 8.05 Billion CHF | 66.63% |
| 2021 Q2 | 9.22 Billion CHF | 74.32% |
| 2020 FY | 18.54 Billion CHF | 5.67% |
| 2020 Q1 | 5.59 Billion CHF | -34.5% |
| 2020 Q2 | 9.84 Billion CHF | 75.87% |
| 2020 Q3 | 4.25 Billion CHF | -56.77% |
| 2020 Q4 | 7.88 Billion CHF | 85.31% |
| 2019 Q4 | 8.54 Billion CHF | 81.07% |
| 2019 Q1 | 5.79 Billion CHF | 37.21% |
| 2019 Q2 | 5.79 Billion CHF | 0.0% |
| 2019 FY | 17.54 Billion CHF | 18.82% |
| 2019 Q3 | 4.71 Billion CHF | -18.65% |
| 2018 Q1 | 5.23 Billion CHF | 34.3% |
| 2018 FY | 14.76 Billion CHF | 13.58% |
| 2018 Q4 | 4.22 Billion CHF | 0.0% |
| 2018 Q3 | 4.22 Billion CHF | -19.23% |
| 2018 Q2 | 5.23 Billion CHF | 0.0% |
| 2017 Q2 | 4.75 Billion CHF | 0.0% |
| 2017 Q1 | 4.75 Billion CHF | 14.68% |
| 2017 FY | 13 Billion CHF | -7.58% |
| 2017 Q4 | 3.89 Billion CHF | 0.0% |
| 2017 Q3 | 3.89 Billion CHF | -18.02% |
| 2016 Q1 | 4.27 Billion CHF | 17.28% |
| 2016 FY | 14.06 Billion CHF | 1.79% |
| 2016 Q2 | 4.27 Billion CHF | 0.0% |
| 2016 Q4 | 4.14 Billion CHF | 0.0% |
| 2016 Q3 | 4.14 Billion CHF | -3.15% |
| 2015 FY | 13.82 Billion CHF | -1.91% |
| 2015 Q1 | 4.07 Billion CHF | 7.7% |
| 2015 Q4 | 3.64 Billion CHF | 0.0% |
| 2015 Q3 | 3.64 Billion CHF | -10.55% |
| 2015 Q2 | 4.07 Billion CHF | 0.0% |
| 2014 Q3 | 3.78 Billion CHF | -15.2% |
| 2014 FY | 14.09 Billion CHF | -13.96% |
| 2014 Q4 | 3.78 Billion CHF | 0.0% |
| 2014 Q2 | 4.46 Billion CHF | 0.0% |
| 2014 Q1 | 4.46 Billion CHF | 14.64% |
| 2013 FY | 16.37 Billion CHF | 15.94% |
| 2013 Q2 | 4.4 Billion CHF | 0.0% |
| 2013 Q3 | 3.89 Billion CHF | -11.6% |
| 2013 Q4 | 3.89 Billion CHF | 0.0% |
| 2013 Q1 | 4.4 Billion CHF | 0.0% |
| 2012 FY | 14.12 Billion CHF | 4.99% |
| 2011 FY | 13.45 Billion CHF | -0.24% |
| 2010 FY | 13.48 Billion CHF | 9.85% |
| 2009 FY | 12.27 Billion CHF | -11.83% |
| 2008 FY | 13.92 Billion CHF | -3.76% |
| 2007 FY | 14.46 Billion CHF | 23.34% |
| 2006 FY | 11.73 Billion CHF | 35.31% |
| 2005 FY | 8.66 Billion CHF | -3.45% |
| 2004 FY | 8.97 Billion CHF | 60.57% |
| 2003 FY | 5.59 Billion CHF | 318.88% |
| 2002 FY | 1.33 Billion CHF | -58.89% |
| 2001 FY | 3.24 Billion CHF | -54.47% |
| 2000 FY | 7.13 Billion CHF | 11.06% |
| 1999 FY | 6.42 Billion CHF | 46.9% |
| 1998 FY | 4.37 Billion CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | -87.904% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | 10.712% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | -119.427% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 38847.106% |
| Novartis AG | 9.76 Billion USD | -57.59% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 99.575% |